Immatics Provides Update on IMA204 ACTengine Cell Therapy Program Targeting the Tumor Microenvironment IMA204 ACTengine cell therapy program directed at novel tumor target COL6A3 exon 6 prevalently expresse

Immatics Provides Update on IMA204 ACTengine

Cell Therapy Program Targeting the Tumor Microenvironment

Tuebingen, Germany and Houston, Texas, September 10, 2020 Immatics N.V. (NASDAQ: IMTX; Immatics ), a

clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its fourth ACTengine cell therapy

program, IMA204. IMA204 is designed to address a novel target, COL6A3 exon 6, which is highly expressed in the stroma of a large number of solid tumors.

Immatics will discuss the IMA204 preclinical data at the Hanson Wade CAR-TCR Digital Week on September

Preclinical data highlights:

Ph.D., Chief Technology Officer at Immatics, commented: Solid tumors develop a complex microenvironment where the tumor stroma plays a crucial role in tumor initiation, progression and metastasis by providing a protective defense layer against

the body s immune system. Taking apart the tumor s defense network with novel and highly potent TCRs directed against the tumor stroma presents a promising opportunity to address hard to treat solid cancers.

About Immatics IMA204 Program

fourth ACTengine IMA204 program targets the tumor stroma and is designed to disrupt the tumor microenvironment. The rigid stroma and the immunosuppressive microenvironment of solid tumors

pose a significant challenge for T cell accessibility and activity and targeting this compartment could provide a novel approach for many solid tumors. Immatics has selected two product candidates for its IMA204 program following the initial

discovery of a novel stroma-associated peptide-HLA complex target using Immatics proprietary XPRESIDENT platform and the design of the right affinity-enhanced TCRs using its XCEPTOR platform. The target is present in high copy numbers in the tumor stroma and is part of the COL6A3 exon 6 protein, an extracellular matrix component that is expressed predominantly by tumor

stroma cells but to a far lower extent in a few healthy tissues.

About Immatics ACT Programs

Immatics clinical product class ACTengine is a personalized approach for patients with advanced

solid cancers. The patient s own T cells are genetically modified to express a novel proprietary TCR against the cancer target that is then infused back into the patient. ACTengine

programs IMA201, IMA202 and IMA203 are already in clinical studies for solid tumor indications,

both in the US and in Germany. Immatics latest proprietary ACTengine manufacturing processes are designed to generate cell product

candidates within a six day manufacturing window and to deliver highly proliferative T cells, with the capability to infiltrate the patient s tumor and function in a challenging solid tumor microenvironment. The process is designed to rapidly

produce younger, better-persisting T cells capable of serial killing tumor cells in vitro. Immatics is further advancing the ACT concept beyond individualized manufacturing with its product class ACTallo which is being developed to generate off-the-shelf cellular therapies.

More information on the clinical trials can be found at the following links: https://immatics.com/clinical-programs/ and

https://clinicaltrials.gov/.

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of

enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with

global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Forward-Looking Statements

Certain statements in this

press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics future financial or operating performance. For example, statements concerning the timing of product candidates

and Immatics focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may , should , expect ,

intend , will , estimate , anticipate , believe , predict , potential or continue , or the negatives of these terms or variations of them or similar

terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking

statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New

risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current

expectations include, but are not limited to, various factors beyond management s control including general economic conditions and other risks, uncertainties and factors set forth in filings with the Securities and Exchange Commission (SEC).

Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You

should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.

For more information, please contact: